The company raised $11.1 million of Series A1 venture funding from Dr. Reddy’s Laboratories and OurCrowdon. The funds will be used to further develop its technology platform which includes performing pre-clinical studies for safety and efficacy evaluation, securing intellectual property through patent filings and exploring licensing opportunities, collaborations and market entry strategies to optimize the commercial viability of the technology platform.